<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00853632</url>
  </required_header>
  <id_info>
    <org_study_id>2006-05</org_study_id>
    <nct_id>NCT00853632</nct_id>
  </id_info>
  <brief_title>Magna® Mitral Pericardial Bioprostheses Post-Approval Study Protocol</brief_title>
  <official_title>Carpentier-Edwards® Perimount Magna® Mitral Pericardial Bioprostheses Models 7000/7000 TFX and Carpentier-Edwards® Perimount Magna® Mitral Ease™ Pericardial Bioprostheses Models 7200TFX and 7300/7300TFX</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to demonstrate the long term safety and effectiveness of the&#xD;
      Carpentier-Edwards® PERIMOUNT Magna Mitral Valves in patients undergoing mitral valve&#xD;
      replacement with or without concomitant procedures requiring cardiopulmonary bypass.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-arm, multi-center study to be conducted in the US and outside&#xD;
      the US (OUS). Approximately 250 subjects are planned to be enrolled to obtain long term data&#xD;
      from 101 subjects at 8 years post implant of the Magna mitral valve. Of these 250,&#xD;
      approximately 38 (15%) are anticipated to be simultaneous aortic and mitral replacements.&#xD;
      Subject enrollment will not start in the US before obtaining FDA approval of this post market&#xD;
      study.&#xD;
&#xD;
      Assessments will be obtained for the preoperative and operative visits, and postoperatively&#xD;
      at discharge, six months, 1-year and annually thereafter for a minimum of 8 years. Subject's&#xD;
      demographics (date of birth, sex), physical assessment (heart rate, height, weight, systolic&#xD;
      and diastolic blood pressures), New York Heart Association (NYHA) functional class, cardiac&#xD;
      rhythm, cardiovascular medical history/risk factors, non-cardiovascular conditions, previous&#xD;
      cardiovascular procedures/interventions, antithromboembolic and lipid lowering medications&#xD;
      and coagulation profile. Blood data will be collected from each subject preoperatively, at 6&#xD;
      months and annually post implant through 8 year follow-ups. Echocardiographic evaluation&#xD;
      required for each subject preoperatively, at discharge, 6 months (between 3-6 months), 1, 2,&#xD;
      4, 6, and 8 year follow-ups. A QOL survey (EQ-5D) will be completed by the subject&#xD;
      pre-operatively and at the 6-month follow-up visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoints</measure>
    <time_frame>Long term safety performance</time_frame>
    <description>Long term safety performance will be evaluated by comparing the linearized rates listed below to the objective performance criteria referenced in ISO 5840- 2005, Cardiovascular Implants-Cardiac Valve Prostheses.&#xD;
Thromboembolism&#xD;
All Hemorrhage&#xD;
All Perivalvular Leak&#xD;
Endocarditis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Effectiveness Endpoints</measure>
    <time_frame>8 years post-implant</time_frame>
    <description>The primary effectiveness endpoint will be the percentage of subjects in NYHA functional classification I or II at 8 years post-implant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Endpoints</measure>
    <time_frame>Long term safety performance</time_frame>
    <description>Early &amp; late linearized &amp; actuarial analysis of:&#xD;
Thromboembolism&#xD;
Valve thrombosis&#xD;
All hemorrhage&#xD;
Major hemorrhage&#xD;
All perivalvular leak&#xD;
Major perivalvular leak&#xD;
Endocarditis&#xD;
Hemolysis&#xD;
Structural valve deterioration&#xD;
Non-structural valve dysfunction&#xD;
Reoperation&#xD;
Explant&#xD;
Death&#xD;
Valve-related death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Endpoints</measure>
    <time_frame>6 month, 1 year and annual follow-up visits</time_frame>
    <description>Blood studies including white blood count, red blood count, hematocrit, plasma free hemoglobin (or haptoglobin and SLDH), platelet and reticulocyte counts will be used to evaluate the rate of hemolysis and adverse events at the 6 month, 1 year and annual follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Effectiveness Endpoints</measure>
    <time_frame>8 years post-implant</time_frame>
    <description>The secondary Effectiveness endpoints will be: Hemodynamic Performance by echocardiography at 8 years post implant, which includes:&#xD;
Peak Gradient&#xD;
Mean Gradient&#xD;
Effective Orifice Area&#xD;
Effective Orifice Area Index&#xD;
Performance Index&#xD;
Cardiac Output&#xD;
Cardiac Index&#xD;
Severity of Valvular Regurgitation&#xD;
LV Mass Regression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Effectiveness Endpoints</measure>
    <time_frame>6 months post-implant</time_frame>
    <description>Quality of Life Survey (EQ-5D) at 6 month post index procedure as compared to preoperative baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Mitral Valve Regurgitation</condition>
  <condition>Mitral Valve Incompetence</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Device - CEP Mitral Valve</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES</intervention_name>
    <description>Mitral valve replacement</description>
    <arm_group_label>Device - CEP Mitral Valve</arm_group_label>
    <other_name>Magna Mitral 7000/7000TFX, Magna Mitral Ease 7200TFX, 7300/7300TFX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient requires, as indicated in the preoperative evaluation, a replacement&#xD;
             mitral valve.&#xD;
&#xD;
          -  The patient has signed and dated the subject informed consent form prior to surgery.&#xD;
&#xD;
          -  The patient is expected to survive the surgery and be discharged.&#xD;
&#xD;
          -  The patient is geographically stable and agrees to attend follow-up assessments.&#xD;
&#xD;
          -  The patient is 18 years or older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient has any known non-cardiac life-threatening disease, which will limit the&#xD;
             patient's life expectancy below 1 year.&#xD;
&#xD;
          -  The patient presents with active endocarditis within the last 3 months.&#xD;
&#xD;
          -  The patient is pregnant or lactating.&#xD;
&#xD;
          -  The patient is an intravenous drug abuser.&#xD;
&#xD;
          -  The patient is currently a prison inmate.&#xD;
&#xD;
          -  The patient is currently participating in a study of an investigational drug or&#xD;
             device.&#xD;
&#xD;
          -  The patient requires replacement of a native or prosthetic tricuspid or pulmonic&#xD;
             valve.&#xD;
&#xD;
          -  The patient requires replacement of a native or prosthetic aortic valve with a&#xD;
             prosthesis other than a commercially available Carpentier-Edwards PERIMOUNT Valve&#xD;
             (i.e. models 2700, 2700TFX, 2800, 2800TFX, 2900, 3000, 3000TFX, 3300TFX)*.&#xD;
&#xD;
          -  The patient was previously enrolled in the study.&#xD;
&#xD;
          -  The patient has had prior aortic, tricuspid and/or pulmonary valve surgery, which&#xD;
             included implantation of a bioprosthetic valve or mechanical valve that will remain in&#xD;
             situ.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Edwards</last_name>
    <role>Study Director</role>
    <affiliation>Edwards Lifesciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dignity Health Research Institute</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospital &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Heart Medical Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical School</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Hospitals</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital, NY</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Hietzing</name>
      <address>
        <city>Vienna</city>
        <zip>A-1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinica Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Friedrich Schiller University</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 26, 2009</study_first_submitted>
  <study_first_submitted_qc>February 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2009</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitral valve</keyword>
  <keyword>pericardial bioprostheses</keyword>
  <keyword>PERIMOUNT</keyword>
  <keyword>bovine pericardial leaflets</keyword>
  <keyword>mitral valve replacement</keyword>
  <keyword>mitral valve regurgitation</keyword>
  <keyword>Heart valve disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

